Tvardi Therapeutics
Biotechnology, 2450 Holcombe BLVD, Houston, Texas, 77021, United States, 1-10 Employees
Phone Number: 83********
Who is TVARDI THERAPEUTICS
Tvardi Therapeutics is a clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic dis...
Read More
-
Headquarters: 2450 Holcombe BLVD, Houston, Texas, 77021, United States
-
Date Founded: 2017
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
-
CEO:
Imran Alibhai
Email
Phone
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from TVARDI THERAPEUTICS
Tvardi Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Tvardi Therapeutics
Answer: Tvardi Therapeutics's headquarters are located at 2450 Holcombe BLVD, Houston, Texas, 77021, United States
Answer: Tvardi Therapeutics's phone number is 83********
Answer: Tvardi Therapeutics's official website is https://tvardi.com
Answer: Tvardi Therapeutics's revenue is Under $1 Million
Answer: Tvardi Therapeutics's SIC: 8731
Answer: Tvardi Therapeutics's NAICS: 541714
Answer: Tvardi Therapeutics has 1-10 employees
Answer: Tvardi Therapeutics is in Biotechnology
Answer: Tvardi Therapeutics contact info: Phone number: 83******** Website: https://tvardi.com
Answer: Tvardi Therapeutics is a clinical stage, private biotechnology company developing a new class of breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases. Founded in 2017 and based in Houston, Texas, the company is led by experienced entrepreneurs, innovative scientists and dedicated physicians. Tvardi is focused on the development of inhibitors of STAT3, a key signaling molecule positioned at the intersection of many pathways controlling gene networks integral to the survival and immune sequestration of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic conditions. Tvardi is conducting a first-in-human Phase Ia dose-escalating study to determine safety and dosing for follow-on studies for its lead compound, TTI-101. Collectively, the societal and economic impact of STAT3-dependent disease is significant. Tvardi is highly motivated to develop safe and effective small molecule inhibitors of STAT3 for use across numerous diseases.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month